Trump Pushes Congress to Save Hemp CBD Before November Recriminalization Deadline

In one of the more unusual political reversals of 2026, President Donald Trump is now urging Congress to undo part of a law that he himself signed just five months ago. The target: a provision in the Continuing Appropriations and Extensions Act of 2026 that threatens to recriminalize the vast majority of hemp-derived products — including many CBD products — when it takes effect on November 13, 2026.

The president's message is straightforward: preserve Americans' access to "full-spectrum CBD products" while maintaining restrictions on hemp-derived products that pose health risks. The execution, however, is anything but simple.

How We Got Here

The backstory requires a brief trip through one of the more chaotic legislative episodes in recent memory.

On November 12, 2025, President Trump signed H.R. 5371 — the spending bill that ended the longest government shutdown in U.S. history. Buried within that massive piece of legislation was a provision that fundamentally rewrites the legal definition of hemp.

The 2018 Farm Bill had defined hemp as cannabis containing less than 0.3% THC by dry weight, effectively legalizing an enormous category of cannabinoid products: CBD oils, tinctures, gummies, delta-8 THC, delta-10 THC, THCA flower, and a dizzying array of other hemp-derived products that had flooded the market.

The new provision in H.R. 5371 dramatically narrows that definition. When the law takes full effect on November 13, 2026 — exactly 365 days after enactment — it will recriminalize the majority of hemp-derived THC products. Delta-8, delta-10, and many other intoxicating hemp derivatives will become federally illegal. And depending on how regulators interpret the new language, even some non-intoxicating CBD products could be caught in the net.

The provision was included at the urging of lawmakers who argued that the unregulated hemp-derived THC market had become a public health concern — that products of wildly varying quality and potency were being sold to consumers, including minors, with virtually no oversight. That argument has merit. What it did not anticipate was the collateral damage to the legitimate CBD industry.

What Trump Is Asking For

The president's position, articulated through statements released this week, draws a distinction between two categories of hemp-derived products.

On one side: full-spectrum CBD products, which contain the full range of naturally occurring cannabinoids in hemp (including trace amounts of THC, typically below 0.3%) and are widely used for wellness, pain management, sleep, and anxiety. Trump wants these preserved.

On the other side: intoxicating hemp-derived products — delta-8 THC, delta-10, and other synthetically converted or concentrated THC products that produce a marijuana-like high. Trump supports maintaining the ban on products that "pose health risks."

The distinction makes intuitive sense to anyone familiar with the market. A grandmother taking a CBD tincture for arthritis is having a fundamentally different experience than a teenager buying delta-8 gummies at a gas station. But translating that intuitive distinction into legally precise language is where things get complicated.

The Legislative Landscape

Multiple bills are already in play. The most prominent is the Hemp Safety Enforcement Act, filed by a bipartisan trio: Senators Rand Paul (R-KY), Amy Klobuchar (D-MN), and Joni Ernst (R-IA). The bill would let states and Indian tribes opt out of the federal recriminalization, essentially creating a state-by-state framework for hemp-derived THC products.

The Paul-Klobuchar-Ernst approach has appeal across the political spectrum. For conservatives, it respects state sovereignty. For progressives, it preserves market access and consumer choice. For the hemp industry, it offers a lifeline.

Other legislative proposals take different approaches — some would create a new federal regulatory framework for hemp-derived cannabinoids, while others would simply extend the November deadline to give Congress more time to develop comprehensive reform.

The House bill to federally legalize marijuana has also gained momentum, picking up three new cosponsors this week for a total of 64. While full federal legalization remains a longer-term project, the growing caucus reflects shifting political winds.

What Is at Stake

The numbers paint a vivid picture of what the November deadline could destroy.

The global CBD market was valued at approximately $16.5 billion in 2025 and is projected to grow to over $24 billion in 2026. The United States represents the largest single national market. Hundreds of thousands of jobs — from hemp farmers to product manufacturers to retail employees — depend on the legal status of CBD and related products.

The broader hemp-derived cannabinoid market, including delta-8 and other THC variants, adds billions more. While this segment has operated in a regulatory gray area, it has also provided legal access to cannabinoid products for consumers in states where marijuana remains illegal.

If the November deadline passes without congressional action, the impact would be sweeping. CBD brands that have invested years in building compliant, quality-tested product lines would suddenly find their products federally illegal. Hemp farmers who planted crops based on existing law would have no legal market for their harvest. And consumers who rely on CBD for pain management, sleep, or anxiety would lose access to products they use daily.

The Industry's Dilemma

For the hemp and CBD industry, Trump's intervention is both welcome and fraught with complexity.

On the positive side, having the president publicly advocate for preserving CBD access gives the reform effort significant political cover. In a Congress that often treats cannabis and hemp issues as low-priority, presidential attention elevates the issue and creates pressure to act.

On the negative side, the president's position also implicitly endorses the ban on intoxicating hemp products — products that represent a significant revenue stream for many hemp companies. The delta-8 market alone was estimated at several billion dollars before the legislative crackdown. Companies that built their business models around these products face an existential threat that Trump's CBD-focused advocacy does not address.

There is also a timing problem. Congress is not known for urgency, and the November deadline is less than seven months away. Drafting legislation, navigating committee markups, reconciling House and Senate versions, and securing floor votes is a process that routinely takes longer than seven months — even for less controversial issues.

The hemp industry is understandably nervous. "From signature to reversal: Trump now wants Congress to undo part of the hemp ban he signed," as the Washington Times headline put it, capturing the whiplash that has defined this issue.

What Consumers Should Know

For the average CBD consumer, the immediate impact is minimal. The current legal framework remains in effect until November 13, 2026. Products that are legal today will remain legal for the next several months.

But consumers should be aware that the landscape could shift dramatically after that date. If Congress fails to act, many of the CBD products currently on shelves could become federally illegal — even if state law permits them.

The safest bet for consumers who depend on CBD products is to stay informed about the legislative process, support advocacy organizations pushing for reform, and consider stocking up on preferred products as the deadline approaches — just in case.

For consumers of delta-8, delta-10, and other hemp-derived THC products, the outlook is less optimistic. Even the most industry-friendly legislative proposals currently under consideration would impose significant restrictions on intoxicating hemp products, and the president's own position explicitly supports maintaining those restrictions.

The Clock Is Ticking

The November 2026 deadline is not a distant abstraction. It is a hard date, written into federal law, with real consequences for businesses, farmers, and consumers across the country.

Trump's push for congressional action introduces a powerful variable into the equation. Whether it is enough to overcome legislative inertia, bridge partisan divides on the specifics of reform, and produce signed legislation before the deadline remains to be seen.

What is clear is that the hemp and CBD industry is facing its most consequential moment since the 2018 Farm Bill opened the floodgates. The question is not whether the law will change — it already has. The question is whether Congress can fix what it broke before the consequences become irreversible.

Seven months. Tick, tick, tick.

Whichever way Congress moves on the hemp deadline, marijuana dispensaries remain the most reliable path to lab-tested cannabinoid products — Budpedia's cannabis dispensary directory covers 7,400+ verified retailers across every legal state.